Inhibition of PFKFB3 in macrophages ameliorates intestinal inflammation by modulating gut microbiota in DSS-induced

Jia-Hui Gao1,2,3, Li-Xiang Li1,2,3, Wei-Jia Li1,2,3

  • 1Department of Gastroenterology, Qilu Hospital, Shandong University, Jinan, China.

Msystems
|December 11, 2025
PubMed

Insights

Phosphofructo-2-kinase/fructose-2,6-biophosphatase 3 (PFKFB3) deficiency in macrophages ameliorates ulcerative colitis (UC) by altering the gut microbiota. This suggests PFKFB3-modulated gut microbiota may offer a novel therapeutic approach for UC.

Area of Science:

  • Immunology
  • Gastroenterology
  • Microbiology

Background:

  • Phosphofructo-2-kinase/fructose-2,6-biophosphatase 3 (PFKFB3) is a key glycolytic enzyme involved in inflammatory responses.
  • The role of PFKFB3 in ulcerative colitis (UC) and its underlying mechanisms remain unclear.

Purpose of the Study:

  • To investigate the role of PFKFB3 in UC pathogenesis.
  • To explore the mechanistic link between PFKFB3, colonic macrophages, and gut microbiota in UC.

Main Methods:

  • Analysis of PFKFB3 expression in human UC cohorts and colitis mouse models.
  • Investigating PFKFB3's role using macrophage-specific PFKFB3 knockout mice (PFKFB3fl/flLyz2-Cre).
  • In silico analysis of transcriptomic data to correlate PFKFB3 with microbiome-associated genes.

Main Results:

  • PFKFB3 expression was significantly upregulated in the colons of UC patients and colitis mice, primarily in macrophages.
  • Macrophage-specific PFKFB3 deficiency alleviated experimental colitis and altered the gut microbiota, enhancing the Faecalibaculum genus.
  • The PFKFB3-modulated gut microbiota was transmissible and conferred protection against colitis, an effect lost with antibiotic treatment.

Conclusions:

  • PFKFB3 in colonic macrophages plays a critical role in UC development.
  • Targeting PFKFB3 in macrophages and modulating the gut microbiota represent a potential novel therapeutic strategy for UC.